Immune cell therapy shows promise for tough lupus cases

NCT ID NCT06265220

Ongoing Disease control Sponsor: Artiva Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called AB-101 for people with lupus nephritis or other hard-to-treat lupus. AB-101 uses donated natural killer cells to boost the body's ability to fight the disease. The study aims to see if this approach is safe and can help patients who have not responded to standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS - WHO CLASS III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS - WHO CLASS III LUPUS NEPHRITIS - WHO CLASS IV REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS SLE

Contacts and locations

Locations

Artiva Investigational Site Aventura

Aventura, Florida, 33180, United States
Artiva Investigational Site Birmingham

Birmingham, Alabama, 35249, United States
Artiva Investigational Site Charlotte

Charlotte, North Carolina, 28625, United States
Artiva Investigational Site Iowa

Iowa City, Iowa, 52242, United States
Artiva Investigational Site Mesquite

Mesquite, Texas, 75150, United States
Artiva Investigational Site Plantation

Plantation, Florida, 33324, United States
Artiva Investigational Site San Diego

San Diego, California, 92121, United States
Artiva Investigational Site Tucson

Tucson, Arizona, 85724, United States
Artiva Investigational Site Woodlands

The Woodlands, Texas, 77382, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.